IN2015DN03928A - - Google Patents

Download PDF

Info

Publication number
IN2015DN03928A
IN2015DN03928A IN3928DEN2015A IN2015DN03928A IN 2015DN03928 A IN2015DN03928 A IN 2015DN03928A IN 3928DEN2015 A IN3928DEN2015 A IN 3928DEN2015A IN 2015DN03928 A IN2015DN03928 A IN 2015DN03928A
Authority
IN
India
Prior art keywords
compound
formula
mek
inhibitor
disclosed
Prior art date
Application number
Other languages
English (en)
Inventor
Sriram Naganathan
Nathan Guz
Matthew Pfeiffer
C Gregory Sowell
Tracy Bostick
Jason Yang
Amit Srivastava
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of IN2015DN03928A publication Critical patent/IN2015DN03928A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
IN3928DEN2015 2012-10-12 2013-10-14 IN2015DN03928A (enEXAMPLES)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713104P 2012-10-12 2012-10-12
PCT/US2013/064866 WO2014059422A1 (en) 2012-10-12 2013-10-14 Novel process for making compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
IN2015DN03928A true IN2015DN03928A (enEXAMPLES) 2015-10-02

Family

ID=49474740

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3928DEN2015 IN2015DN03928A (enEXAMPLES) 2012-10-12 2013-10-14

Country Status (31)

Country Link
US (4) US9771347B2 (enEXAMPLES)
EP (1) EP2909188B1 (enEXAMPLES)
JP (2) JP6300042B2 (enEXAMPLES)
KR (1) KR102204520B1 (enEXAMPLES)
CN (2) CN104837826B (enEXAMPLES)
AU (1) AU2013328929B2 (enEXAMPLES)
BR (1) BR112015008113B1 (enEXAMPLES)
CA (1) CA2889466C (enEXAMPLES)
CL (1) CL2015000926A1 (enEXAMPLES)
CR (2) CR20200237A (enEXAMPLES)
EA (1) EA030613B1 (enEXAMPLES)
ES (1) ES2671502T3 (enEXAMPLES)
GE (1) GEP201706690B (enEXAMPLES)
HK (1) HK1213567A1 (enEXAMPLES)
HR (1) HRP20180670T1 (enEXAMPLES)
IL (1) IL238116B (enEXAMPLES)
IN (1) IN2015DN03928A (enEXAMPLES)
MA (1) MA38085B1 (enEXAMPLES)
MX (2) MX372708B (enEXAMPLES)
MY (1) MY186549A (enEXAMPLES)
NZ (1) NZ706723A (enEXAMPLES)
PE (3) PE20151494A1 (enEXAMPLES)
PH (1) PH12015500785B1 (enEXAMPLES)
PL (1) PL2909188T3 (enEXAMPLES)
SA (1) SA515360271B1 (enEXAMPLES)
SG (1) SG11201502795VA (enEXAMPLES)
SI (1) SI2909188T1 (enEXAMPLES)
TR (1) TR201807861T4 (enEXAMPLES)
UA (1) UA115455C2 (enEXAMPLES)
WO (1) WO2014059422A1 (enEXAMPLES)
ZA (1) ZA201502349B (enEXAMPLES)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6300042B2 (ja) 2012-10-12 2018-03-28 エグゼリクシス, インコーポレイテッド 癌の処置に使用するための化合物の製造方法
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
ES2871175T3 (es) 2015-06-30 2021-10-28 Genentech Inc Comprimidos de liberación inmediata que contienen un fármaco y procesos para la formación de los comprimidos
CN105330643B (zh) * 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
CN109689102A (zh) 2016-08-12 2019-04-26 基因泰克公司 Mek抑制剂,pd-1轴抑制剂,和vegf抑制剂的组合疗法
AU2017335839A1 (en) 2016-09-29 2019-04-18 Genentech, Inc. Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a taxane
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
JP2024509269A (ja) 2021-03-09 2024-02-29 ジェネンテック, インコーポレイテッド 脳がんの治療における使用のためのベルバラフェニブ
EP4319749A1 (en) 2021-04-06 2024-02-14 Genentech, Inc. Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1563587A (en) * 1924-09-20 1925-12-01 Raney Murray Method of preparing catalytic material
US1628190A (en) * 1926-05-14 1927-05-10 Raney Murray Method of producing finely-divided nickel
US1915473A (en) * 1930-12-31 1933-06-27 Raney Murray Method of preparing catalytic material
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
US6048885A (en) 1994-04-01 2000-04-11 Shionogi & Co., Ltd. Oxime derivative and bactericide containing the same as active ingredient
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AU5610398A (en) 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
EP0993437B1 (en) * 1997-07-01 2006-11-08 Warner-Lambert Company Llc 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
ES2229515T3 (es) 1997-07-01 2005-04-16 Warner-Lambert Company Llc Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
WO2000035435A1 (en) 1998-12-15 2000-06-22 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
WO2000035436A2 (en) 1998-12-16 2000-06-22 Warner-Lambert Company Treatment of arthritis with mek inhibitors
CA2352326A1 (en) 1998-12-22 2000-06-29 Warner-Lambert Company Combination chemotherapy
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
DE69924641D1 (de) 1999-01-07 2005-05-12 Warner Lambert Company Llc Mor Behandlung von asthma anhand von mek-inhibitoren
EP1140067A1 (en) 1999-01-07 2001-10-10 Warner-Lambert Company Antiviral method using mek inhibitors
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
ES2252996T3 (es) 1999-01-13 2006-05-16 Warner-Lambert Company Llc Derivados de bencenosulfonamida y su uso como inhibidores de mek.
GEP20032999B (en) 1999-01-13 2003-06-25 Warner Lambert Co 1-Heterocycle Substituted Diarylamines
HK1041697A1 (zh) 1999-01-13 2002-07-19 沃尼尔‧朗伯公司 苯并杂环和它们作为mek抑制剂的用途
AU2483400A (en) 1999-01-13 2000-08-01 Warner-Lambert Company 4'heteroaryl diarylamines
WO2001005390A2 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
HUP0202180A3 (en) 1999-07-16 2004-10-28 Warner Lambert Co Method for treating chronic pain using mek inhibitors
EP1202732A2 (en) 1999-07-16 2002-05-08 Warner-Lambert Company Llc Method for treating chronic pain using mek inhibitors
AU5786000A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
KR20020047175A (ko) 1999-09-17 2002-06-21 밀레니엄 파머슈티컬스 인코퍼레이티드 Xa 인자의 억제제
JP2003527379A (ja) 2000-03-15 2003-09-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Mex阻害物質としての5−アミド置換ジアリールアミン類
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
IL153817A0 (en) 2000-07-19 2003-07-31 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
CA2420003A1 (en) * 2000-08-25 2002-03-07 Derick Dale Winkle Process for making n-aryl-anthranilic acids and their derivatives
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
US7085492B2 (en) 2001-08-27 2006-08-01 Ibsen Photonics A/S Wavelength division multiplexed device
CA2460118A1 (en) 2001-10-31 2003-05-08 Pfizer Products Inc. Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
BR0307060A (pt) 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
PL378635A1 (pl) 2002-03-13 2006-05-15 Array Biopharma, Inc. N3 alkilowane pochodne benzoimidazolu jako inhibitory MEK
PL401637A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
JP4245561B2 (ja) 2002-06-11 2009-03-25 メルク エンド カムパニー インコーポレーテッド (ハロ−ベンゾカルボニル)複素2環p38キナーゼ阻害剤
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
WO2004004644A2 (en) 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
RU2357957C2 (ru) 2003-03-03 2009-06-10 Эррэй Биофарма, Инк. Ингибиторы р38 и способы их применения
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
EA010297B1 (ru) 2003-06-20 2008-08-29 ЮСиБи ФАРМА С.А. Производные тиенопиридона как ингибиторы киназ
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
ES2331246T3 (es) 2003-07-24 2009-12-28 Warner-Lambert Company Llc Derivados de benzamidazol como inhibidores del mek.
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP4931419B2 (ja) 2003-09-19 2012-05-16 中外製薬株式会社 新規4−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
DK1682138T3 (da) 2003-11-19 2011-04-18 Array Biopharma Inc Heterocykliske inhibitorer af MEK
EP1694673B1 (en) 2003-12-08 2008-01-16 F.Hoffmann-La Roche Ag Thiazole derivates
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
MX2007004781A (es) 2004-10-20 2007-05-11 Applied Research Systems Derivados de 3-arilamino piridina.
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
DK1934174T3 (da) * 2005-10-07 2011-08-01 Exelixis Inc Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
CN105106199A (zh) * 2006-12-14 2015-12-02 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
JP6300042B2 (ja) 2012-10-12 2018-03-28 エグゼリクシス, インコーポレイテッド 癌の処置に使用するための化合物の製造方法
CN105992755B (zh) 2014-02-07 2018-07-13 住友化学株式会社 (r)-1,1,3-三甲基-4-氨基茚满的制造方法
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
IL238116B (en) 2018-06-28
US10793541B2 (en) 2020-10-06
US10239858B2 (en) 2019-03-26
CA2889466A1 (en) 2014-04-17
US11414396B2 (en) 2022-08-16
HRP20180670T1 (hr) 2018-07-13
MX2020005533A (es) 2020-10-12
SA515360271B1 (ar) 2016-05-19
CR20150245A (es) 2015-11-19
PL2909188T3 (pl) 2018-08-31
KR102204520B1 (ko) 2021-01-20
CN104837826A (zh) 2015-08-12
EA201590700A1 (ru) 2015-09-30
PE20200387A1 (es) 2020-02-24
CA2889466C (en) 2021-09-14
MA38085B1 (fr) 2018-11-30
US20190185447A1 (en) 2019-06-20
MY186549A (en) 2021-07-26
BR112015008113B1 (pt) 2022-05-24
AU2013328929B2 (en) 2018-01-04
CL2015000926A1 (es) 2015-08-28
BR112015008113A2 (pt) 2017-07-04
PH12015500785A1 (en) 2015-06-15
CR20200237A (es) 2020-07-26
SI2909188T1 (en) 2018-07-31
HK1213567A1 (zh) 2016-07-08
KR20150067339A (ko) 2015-06-17
WO2014059422A1 (en) 2014-04-17
US20170349569A1 (en) 2017-12-07
JP2018052973A (ja) 2018-04-05
US20150210668A1 (en) 2015-07-30
CN108948043B (zh) 2021-05-04
CN108948043A (zh) 2018-12-07
SG11201502795VA (en) 2015-05-28
US20200392104A1 (en) 2020-12-17
JP6300042B2 (ja) 2018-03-28
PE20151494A1 (es) 2015-11-06
ZA201502349B (en) 2019-12-18
PH12015500785B1 (en) 2015-06-15
UA115455C2 (uk) 2017-11-10
EA030613B1 (ru) 2018-08-31
NZ706723A (en) 2018-07-27
EP2909188A1 (en) 2015-08-26
MX372708B (es) 2020-05-29
PE20191818A1 (es) 2019-12-27
EP2909188B1 (en) 2018-03-07
CN104837826B (zh) 2018-07-27
MA38085A1 (fr) 2018-08-31
JP2015533175A (ja) 2015-11-19
TR201807861T4 (tr) 2018-06-21
MX2015004660A (es) 2015-08-07
AU2013328929A1 (en) 2015-04-30
US9771347B2 (en) 2017-09-26
GEP201706690B (en) 2017-06-26
HK1213878A1 (en) 2016-07-15
ES2671502T3 (es) 2018-06-06

Similar Documents

Publication Publication Date Title
IN2015DN03928A (enEXAMPLES)
PH12015502284B1 (en) Protein kinase inhibitors
NZ705705A (en) Ret inhibitor
PH12016500225A1 (en) Novel quinoline-substituted compound
MA40076A (fr) Inhibiteurs de syk
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
IN2015DN02929A (enEXAMPLES)
UA116239C2 (uk) Нові похідні піридину
TN2013000400A1 (en) Imidazopyridazines as akt kinase inhibitors
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
NZ736970A (en) Process methods for phosphatidylinositol 3-kinase inhibitors
PH12017500747A1 (en) Heterocyclic compound
MX351863B (es) Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
IN2014DN10658A (enEXAMPLES)
MX2015012523A (es) Metodos para elaborar composiciones antineoplasicas.
IN2014KN01772A (enEXAMPLES)
GEP20176633B (en) Use of pidotimod to treat psoriasis
MY177247A (en) Method of production of human insulin methyl ester
IN2013MU02595A (enEXAMPLES)
GEP201706683B (en) Usage of pidotimod to treat inflammatory bowel diseases